KYFIL 30MG INJECTION

About

Kyfil, likely a granulocyte colony-stimulating factor (G-CSF), is a recombinant protein that stimulates the production, maturation, and activation of neutrophils from bone marrow stem cells. It plays a crucial role in managing chemotherapy-induced neutropenia, a common and serious side effect of many cancer treatments that increases the risk of life-threatening infections. By increasing neutrophil counts, Kyfil helps to reduce the incidence, severity, and duration of neutropenia, allowing patients to maintain their chemotherapy schedules and reduce the risk of febrile neutropenia. It is also used for other conditions involving neutropenia, such as severe chronic neutropenia and for mobilization of hematopoietic progenitor cells for collection.

Uses

• Chemotherapy-induced neutropenia
• Severe chronic neutropenia
• Mobilization of hematopoietic progenitor cells
• Neutropenia associated with bone marrow transplant

Directions For Use

This medication is administered as a subcutaneous injection, typically once daily. Your healthcare provider will instruct you on the proper technique for self-administration if applicable.

Benefits

• Reduces the incidence and duration of febrile neutropenia.
• Allows patients to receive planned chemotherapy doses on schedule.
• Decreases the risk of serious infections during cancer treatment.
• Enhances recovery of white blood cell counts after chemotherapy.
• Improves patient safety and tolerability of cancer therapy.
• Supports bone marrow function in various neutropenic conditions.

Side Effects

• Bone pain
• Muscle pain
• Headache
• Fatigue
• Nausea
• Diarrhea
• Injection site reactions
• Splenomegaly (enlarged spleen)
• Allergic reactions
• Leukocytosis (high white blood cell count)
• Thrombocytopenia (low platelet count)
• Acute respiratory distress syndrome (ARDS)

Safety Measures

• Alcohol - No specific contraindication, but excessive alcohol may exacerbate general fatigue or discomfort.
• Pregnancy - Use only if the potential benefit justifies the potential risk to the fetus. Animal studies have shown adverse effects.
• Breastfeeding - It is unknown if Kyfil is excreted in human milk. Caution should be exercised when administered to a breastfeeding woman.
• Liver - No specific dose adjustments are typically required for liver impairment, but monitor overall patient condition.
• Kidney - No specific dose adjustments are typically required for renal impairment, but monitor overall patient condition.
• Lung - Monitor for new or worsening pulmonary symptoms, including cough, fever, or dyspnea, as ARDS or alveolar hemorrhage can occur rarely.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.